Research and development of protein arrays and their applications in proteomics

+44 (0)1223 496557

MENU menu

Close close menu

The Team

Dr Mike Taussig - Founder and CEO


Mike Taussig was formerly head of the Protein Technology Group at the Babraham Institute, Cambridge UK. He has collaborated on the production of human antibodies from transgenic mice and codeveloped ribosome display technology, for selection of antibodies, and in situ protein arraying. He helped to establish two Institute spinout companies, Translocus Therapeutics and Discerna, and is a named co-inventor on patents for eukaryotic ribosome display and in situ protein arrays. Mike has wide experience of managing large EU and ESF networking and research projects, including three EU consortia aiming to establish European resources of affinity binding reagents for analysis of the human proteome, namely ProteomeBinders (2006-2010), AffinityProteome (2009-2012) and AFFINOMICS (2010-2015). He is a board member of the European Federation of Biotechnology and Editor in Chief of the EFB journal New Biotechnology (Elsevier). Mike is a Fellow of Selwyn College, Cambridge, where until recently he taught pathology.

Dr Taussig

Dr Oda Stoevesandt - CTO


Oda Stoevesandt has a background in biochemistry and physical chemistry, her main interest is in the parallel detection of biomolecular interactions. During her PhD at the University of Tübingen, Gemany, she developed methods for the detection of protein-protein interactions based on fluorescence cross correlation spectroscopy, before moving into the field of peptide and protein microarrays. At the Babraham Institute (Cambridge, UK) she optimised a protein array based method for cell free protein expression from a re-useable DNA template. Oda has been with Cambridge Protein Arrays Ltd. since the company's set-up , and now serves as Chief Technical Officer. 

Oda Stoevesandt

Cláudia Fonseca - COO


Cláudia Fonseca graduated in biological sciences from the University of Porto and subsequently was a research scientist at Ablynx, a leading biotechnology company developing single domain nanobodies, first in Porto and then in Ghent where her responsibilities were mainly in phage display of nanobodies. She joined the Babraham Institute as a research scientist in the Protein Technology Group in January 2014 and became a permanent staff member of Cambridge Protein Arrays Ltd. in June 2015. Her laboratory skills include different aspects of protein array systems, including design, preparation, sample processing and data analysis. In addition, she serves on the editorial team of the EFB journal New Biotechnology.

Claudia Fonseca

Dr Karsten Köhler - CBO


Karsten Köhler completed his PhD in biochemistry/immunology at the University of Tübingen, Germany, in the field of application of microarrays for the analysis of immune cell signalling, continued by postdoctoral research at Imperial College London and the University of Cambridge. He then moved into biotech at Fahy Gurteen Labs Ltd., Cambridge, before joining CPA in 2016. Throughout his career, he has kept a strong focus on assay development and analysis using innovative platforms, including various array formats. In his additional function, he is responsible for product marketing.

Karsten Koehler